DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX) and the Company’s clinical collaborators reported new clinical data demonstrating a significant correlation between serum levels of the Company’s patented AtherOx™ bio-markers and cardiovascular disease. The data was presented at the XXIst Congress of the International Society on Thrombosis and Hemostasis (ISTH) in Geneva, Switzerland.
